Pirinka Georgiev Tuttle
Pirinka Georgiev Tuttle has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Mar Santamaria
Pfizer, Inc
3 shared publicationsAnna Gao
Pfizer, Inc
2 shared publications- Bhavna Adhin
Pfizer, Inc
2 shared publications Briana Peterson
Pfizer, Inc
2 shared publications- Bunmi Williams
Pfizer, Inc
2 shared publications Charmaine Demanuele
Pfizer, Inc., Cambridge, USA
2 shared publications
Latest Publications
- Open Access
- 13 June 2026
- Published by Taylor & Francis in Bioanalysis
- Vol. 18 (8-9) , 691-700
Limited agreement of cytokines and CRP through patient-centric microsampling compared to venipuncture in healthy adults
1. Venous blood draws are used extensively in patient standard of care and clinical trials for health monitoring. Patient-centric sampling (PCS) focuses on patients’ needs and comfort in its design...
- 13 June 2026
- Published by Taylor & Francis in Bioanalysis
- Vol. 18 (8-9) , 691-700
Open AccessLimited agreement of cytokines and CRP through patient-centric microsampling compared to venipuncture in healthy adults
1. Venous blood draws are used extensively in patient standard of care and clinical trials for health monitoring. Patient-centric sampling (PCS) focuses on patients’ needs and comfort in its design...
- Open Access
- 3 June 2025
- Published by Taylor & Francis in Bioanalysis
- Vol. 17 (11) , 707-723
Quantitation of BCAA and BCKA in plasma and patient-centric dried blood microsamples in a clinical setting
This study assessed the agreement and bias of three dried blood patient-centric microsampling (PCS) devices (paper DBS, Mitra, and Tasso-M20) for the quantitation of branched chain amino acids (BCAAs) and ketoacids (BCKAs) compared to venous plasma samples. Concentrations of BCAAs and BCKAs were measured in samples from generally healthy participants with a validated assay for venous plasma adapted for use with dried blood from the PCS devices. Participants were also asked to respond to a device usability questionnaire about their experience with the devices. The correlations between BCAA/BCKA concentration values in PCS devices vs venipuncture samples were strong to excellent for all six analytes, across all three PCS devices. The surrogate analyte approach facilitated method transfer from plasma to dried blood microsampling devices. Overall, participants reported that they enjoyed using the devices compared to traditional venipuncture and would be willing to use them again, on their own at-home. These study results demonstrate the feasibility of quantitating BCAAs and BCKAs reliably with PCS devices, with high acceptability from study participants.
- 3 June 2025
- Published by Taylor & Francis in Bioanalysis
- Vol. 17 (11) , 707-723
Open AccessQuantitation of BCAA and BCKA in plasma and patient-centric dried blood microsamples in a clinical setting
This study assessed the agreement and bias of three dried blood patient-centric microsampling (PCS) devices (paper DBS, Mitra, and Tasso-M20) for the quantitation of branched chain amino acids (BCAAs) and ketoacids (BCKAs) compared to venous plasma samples. Concentrations of BCAAs and BCKAs were measured in samples from generally healthy participants with a validated assay for venous plasma adapted for use with dried blood from the PCS devices. Participants were also asked to respond to a device usability questionnaire about their experience with the devices. The correlations between BCAA/BCKA concentration values in PCS devices vs venipuncture samples were strong to excellent for all six analytes, across all three PCS devices. The surrogate analyte approach facilitated method transfer from plasma to dried blood microsampling devices. Overall, participants reported that they enjoyed using the devices compared to traditional venipuncture and would be willing to use them again, on their own at-home. These study results demonstrate the feasibility of quantitating BCAAs and BCKAs reliably with PCS devices, with high acceptability from study participants.
- Open Access
- 21 March 2024
- Published by Springer Nature in Pediatric Research
- Vol. 96 (3) , 750-758
Monitoring Activity and Gait in Children (MAGIC) using digital health technologies
Background: Digital health technologies (DHTs) can collect gait and physical activity in adults, but limited studies have validated these in children. This study compared gait and physical activity metrics collected using DHTs to those collected by reference comparators during in-clinic sessions, to collect a normative accelerometry dataset, and to evaluate participants’ comfort and their compliance in wearing the DHTs at-home. Methods: The MAGIC (Monitoring Activity and Gait in Children) study was an analytical validation study which enrolled 40, generally healthy participants aged 3–17 years. Gait and physical activity were collected using DHTs in a clinical setting and continuously at-home. Results: Overall good to excellent agreement was observed between gait metrics extracted with a gait algorithm from a lumbar-worn DHT compared to ground truth reference systems. Majority of participants either “agreed” or “strongly agreed” that wrist and lumbar DHTs were comfortable to wear at home, respectively, with 86% (wrist-worn DHT) and 68% (lumbar-worn DHT) wear-time compliance. Significant differences across age groups were observed in multiple gait and activity metrics obtained at home. Conclusions: Our findings suggest that gait and physical activity data can be collected from DHTs in pediatric populations with high reliability and wear compliance, in-clinic and in home environments. Trial registration: ClinicalTrials.gov: NCT04823650 Impact: Digital health technologies (DHTs) have been used to collect gait and physical activity in adult populations, but limited studies have validated these metrics in children. The MAGIC study comprehensively validates the performance and feasibility of DHT-measured gait and physical activity in the pediatric population. Our findings suggest that reliable gait and physical activity data can be collected from DHTs in pediatric populations, with both high accuracy and wear compliance both in-clinic and in home environments. The identified across-age-group differences in gait and activity measurements highlighted their potential clinical value.
- 21 March 2024
- Published by Springer Nature in Pediatric Research
- Vol. 96 (3) , 750-758
Open AccessMonitoring Activity and Gait in Children (MAGIC) using digital health technologies
Background: Digital health technologies (DHTs) can collect gait and physical activity in adults, but limited studies have validated these in children. This study compared gait and physical activity metrics collected using DHTs to those collected by reference comparators during in-clinic sessions, to collect a normative accelerometry dataset, and to evaluate participants’ comfort and their compliance in wearing the DHTs at-home. Methods: The MAGIC (Monitoring Activity and Gait in Children) study was an analytical validation study which enrolled 40, generally healthy participants aged 3–17 years. Gait and physical activity were collected using DHTs in a clinical setting and continuously at-home. Results: Overall good to excellent agreement was observed between gait metrics extracted with a gait algorithm from a lumbar-worn DHT compared to ground truth reference systems. Majority of participants either “agreed” or “strongly agreed” that wrist and lumbar DHTs were comfortable to wear at home, respectively, with 86% (wrist-worn DHT) and 68% (lumbar-worn DHT) wear-time compliance. Significant differences across age groups were observed in multiple gait and activity metrics obtained at home. Conclusions: Our findings suggest that gait and physical activity data can be collected from DHTs in pediatric populations with high reliability and wear compliance, in-clinic and in home environments. Trial registration: ClinicalTrials.gov: NCT04823650 Impact: Digital health technologies (DHTs) have been used to collect gait and physical activity in adult populations, but limited studies have validated these metrics in children. The MAGIC study comprehensively validates the performance and feasibility of DHT-measured gait and physical activity in the pediatric population. Our findings suggest that reliable gait and physical activity data can be collected from DHTs in pediatric populations, with both high accuracy and wear compliance both in-clinic and in home environments. The identified across-age-group differences in gait and activity measurements highlighted their potential clinical value.
- Open Access
- 4 July 2022
- Published by S. Karger AG in Digital Biomarkers
- Vol. 6 (2) , 47-60
Considerations for Conducting Bring Your Own “Device” (BYOD) Clinical Studies
Background: Digital health technologies are attracting attention as novel tools for data collection in clinical research. They present alternative methods compared to in-clinic data collection, which often yields snapshots of the participants’ physiology, behavior, and function that may be prone to biases and artifacts, e.g., white coat hypertension, and not representative of the data in free-living conditions. Modern digital health technologies equipped with multi-modal sensors combine different data streams to derive comprehensive endpoints that are important to study participants and are clinically meaningful. Used for data collection in clinical trials, they can be deployed as provisioned products where technology is given at study start or in a bring your own “device” (BYOD) manner where participants use their technologies to generate study data. Summary: The BYOD option has the potential to be more user-friendly, allowing participants to use technologies that they are familiar with, ensuring better participant compliance, and potentially reducing the bias that comes with introducing new technologies. However, this approach presents different technical, operational, regulatory, and ethical challenges to study teams. For example, BYOD data can be more heterogeneous, and recruiting historically underrepresented populations with limited access to technology and the internet can be challenging. Despite the rapid increase in digital health technologies for clinical and healthcare research, BYOD use in clinical trials is limited, and regulatory guidance is still evolving. Key Messages: We offer considerations for academic researchers, drug developers, and patient advocacy organizations on the design and deployment of BYOD models in clinical research. These considerations address: (1) early identification and engagement with internal and external stakeholders; (2) study design including informed consent and recruitment strategies; (3) outcome, endpoint, and technology selection; (4) data management including compliance and data monitoring; (5) statistical considerations to meet regulatory requirements. We believe that this article acts as a primer, providing insights into study design and operational requirements to ensure the successful implementation of BYOD clinical studies.
- 4 July 2022
- Published by S. Karger AG in Digital Biomarkers
- Vol. 6 (2) , 47-60
Open AccessConsiderations for Conducting Bring Your Own “Device” (BYOD) Clinical Studies
Background: Digital health technologies are attracting attention as novel tools for data collection in clinical research. They present alternative methods compared to in-clinic data collection, which often yields snapshots of the participants’ physiology, behavior, and function that may be prone to biases and artifacts, e.g., white coat hypertension, and not representative of the data in free-living conditions. Modern digital health technologies equipped with multi-modal sensors combine different data streams to derive comprehensive endpoints that are important to study participants and are clinically meaningful. Used for data collection in clinical trials, they can be deployed as provisioned products where technology is given at study start or in a bring your own “device” (BYOD) manner where participants use their technologies to generate study data. Summary: The BYOD option has the potential to be more user-friendly, allowing participants to use technologies that they are familiar with, ensuring better participant compliance, and potentially reducing the bias that comes with introducing new technologies. However, this approach presents different technical, operational, regulatory, and ethical challenges to study teams. For example, BYOD data can be more heterogeneous, and recruiting historically underrepresented populations with limited access to technology and the internet can be challenging. Despite the rapid increase in digital health technologies for clinical and healthcare research, BYOD use in clinical trials is limited, and regulatory guidance is still evolving. Key Messages: We offer considerations for academic researchers, drug developers, and patient advocacy organizations on the design and deployment of BYOD models in clinical research. These considerations address: (1) early identification and engagement with internal and external stakeholders; (2) study design including informed consent and recruitment strategies; (3) outcome, endpoint, and technology selection; (4) data management including compliance and data monitoring; (5) statistical considerations to meet regulatory requirements. We believe that this article acts as a primer, providing insights into study design and operational requirements to ensure the successful implementation of BYOD clinical studies.